Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 144   

Articles published

GSK 1,640.08 +7.58 (0.46%)
price chart
GlaxoSmithKline plc 12.1% Potential Upside Indicated by Berenberg
GlaxoSmithKline plc with EPIC/TICKER LON:GSK had its stock rating noted as 'Reiterates' with the recommendation being set at 'HOLD' this morning by analysts at Berenberg.
Pacad Investment Ltd. Purchases New Position in GlaxoSmithKline PLC (GSK)  Sports Perspectives
The GlaxoSmithKline plc (GSK) PT Raised to GBX 1650  DailyQuint
Could BP plc and GlaxoSmithKline plc help you retire early?
BP (LSE: BP) is one of the UK market's most trusted dividend stocks and so is its blue-chip peer GlaxoSmithKline (LSE: GSK). Together these two FTSE 100 dividend champions are are responsible for a huge chunk of the total value of dividends paid out to ...
Drugs-crazed shoot-out: which investment is best out of Astra, Glaxo and Shire?
On a forward earnings multiple, again there is nothing between GSK and AZ (15 times 2017 EPS vs 15.6). Shire, however, comes in significantly cheaper at just 13 times - with that comes underlying earnings growth of 11% this year.
Are shares in GlaxoSmithKline plc now in bargain territory?
Shares in FTSE 100 pharmaceutical giant GlaxoSmithKline (LSE: GSK) were in the red this afternoon. That was despite the company reporting a 21% rise in sales (in sterling terms) over the fourth quarter and “continued momentum” in 2016 as a whole.
GSK a 'decent risk-reward trade'; shares could top �17
GlaxoSmithKline plc (LON:GSK) shares are on track to re-test their previous 52-week highs of over �17, according to technical analyst Zak Mir.
Glaxo braces itself for �1bn Advair hit
GlaxoSmithKline plc (LON:GSK) expects to make further progress this year, but warned over the possible impact of generic competition to its Advair asthma drug stateside.
GlaxoSmithKline Plc (GSK) Q4 2016 Results - Earnings Call Transcript  Seeking Alpha
GlaxoSmithKline Up Slightly After Results (GSK)  Investopedia
GSK announces positive study results for HIV treatment
The study, carried out by GSK's majority owned ViiV Healthcare business, showed the two drug treatment for HIV-1 was just as effective as the three or four drug regimens in virologically suppressed patients.
GlaxoSmithKline plc (ADR)(NYSE:GSK) Two-Drug Cocktail Aims Decrease HIV ...  Market Exclusive
GSK: ViiV Healthcare Shows Positive Study Results For Two-drug Regimen For HIV  RTT News
GlaxoSmithKline Breaks Above 200-Day Moving Average - Bullish for GSK
In trading on Thursday, shares of GlaxoSmithKline plc (Symbol: GSK) crossed above their 200 day moving average of $41.38, changing hands as high as $41.60 per share.
GlaxoSmithKline plc 21% Potential Upside Indicated by Liberum Capital
GlaxoSmithKline plc using EPIC/TICKER code LON:GSK has had its stock rating noted as 'Reiterates' with the recommendation being set at 'BUY' today by analysts at Liberum Capital.
GlaxoSmithKline plc (GSK) Earns Buy Rating from Beaufort Securities  Sports Perspectives
Insider Trading at GlaxoSmithKline plc?  Chaffey Breeze
Market Risers: AstraZeneca plc, Barclays PLC, BP plc, GlaxoSmithKline plc
Shares of AstraZeneca plc company symbol: LON:AZN has stepped up 1.43% or 64 points throughout today's trading session so far.
GlaxoSmithKline plc (GSK) Given a GBX 1700 Price Target at Morgan Stanley  Sports Perspectives
The GlaxoSmithKline plc's (GSK) “Neutral” Rating Reiterated at JP Morgan ...  DailyQuint